Post by Secarna Pharmaceuticals

Join Secarna Pharmaceuticals's CRO Richard Klar at #AACR2026 in San Diego! Richard will present additional preclinical and translational data on our proprietary antisense oligonucleotide (ASO) SECN-15 in a poster presentation on Monday, April 20, 2026.   “As we continue our preparations for the first-in-human clinical trials, these additional findings reinforce our approach to establish SECN-15 as promising new therapeutic strategy to target solid tumors.”   See our press release for more information https://lnkd.in/dYxNRrUr